These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9121269)

  • 61. [Antiandrogen].
    Imamoto T; Kawamura K; Ichikawa T
    Nihon Rinsho; 2016 May; 74 Suppl 3():573-7. PubMed ID: 27344796
    [No Abstract]   [Full Text] [Related]  

  • 62. Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives.
    Jacobson O; Bechor Y; Icar A; Novak N; Birman A; Marom H; Fadeeva L; Golan E; Leibovitch I; Gutman M; Even-Sapir E; Chisin R; Gozin M; Mishani E
    Bioorg Med Chem; 2005 Nov; 13(22):6195-205. PubMed ID: 16054371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of the non-steroidal antiandrogen flutamide on neural receptor binding of testosterone and intermale aggressive behavior in mice.
    Clark CR; Nowell NW
    Psychoneuroendocrinology; 1980 Jan; 5(1):39-45. PubMed ID: 7190313
    [No Abstract]   [Full Text] [Related]  

  • 64. Cost-effectiveness of prostate cancer screening and treatment.
    Bilgrami S; Greenberg B
    Ann Intern Med; 1993 Nov; 119(10):1054-5. PubMed ID: 8214992
    [No Abstract]   [Full Text] [Related]  

  • 65. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
    Schulz M; Schmoldt A; Donn F; Becker H
    Eur J Clin Pharmacol; 1988; 34(6):633-6. PubMed ID: 3169114
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?
    Aragon-Ching JB
    Chin Clin Oncol; 2023 Apr; 12(2):12. PubMed ID: 37038056
    [No Abstract]   [Full Text] [Related]  

  • 67. Genetic evidence to exclude the androgen receptor co-factor, ARA70 (NCOA4) as a candidate gene for the causation of undermasculinised genitalia.
    Lim HN; Hawkins JR; Hughes IA
    Clin Genet; 2001 Apr; 59(4):284-6. PubMed ID: 11298686
    [No Abstract]   [Full Text] [Related]  

  • 68. Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide.
    Bergman L; Eriksson E
    Acta Psychiatr Scand; 1996 Aug; 94(2):137-9. PubMed ID: 8883576
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CMA mediates resistance to androgen inhibitors in prostate cancer.
    Masone MC
    Nat Rev Urol; 2023 Mar; 20(3):129. PubMed ID: 36750650
    [No Abstract]   [Full Text] [Related]  

  • 70. Antiandrogen and antineoplastic effects of a novel drug, CPC10997.
    Ford LC; Kasha W; Chang NH; DeLange RJ
    Chemotherapy; 1985; 31(5):362-5. PubMed ID: 3840430
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk of false positive results to SARM S-4 in case of therapeutic use of antineoplastic/antiandrogen drug containing flutamide: a case study.
    Perrenoud L; Schweizer Grundisch C; Baume N; Saugy M; Nicoli R
    Drug Test Anal; 2016 Nov; 8(11-12):1109-1113. PubMed ID: 27511110
    [No Abstract]   [Full Text] [Related]  

  • 72. New and validated high-performance liquid chromatographic method for determination of hydroxyflutamide in human plasma.
    Leibinger J; Kapás M
    J Pharm Biomed Anal; 1996 Jun; 14(8-10):1377-81. PubMed ID: 8818060
    [No Abstract]   [Full Text] [Related]  

  • 73. Evaluation of drug-induced prostatic involution in dogs by transabdominal B-mode ultrasonography.
    Cartee RE; Rumph PF; Kenter DC; Cooney JC; Frank D; Haught J; Leong P; Humphries M; Amaratunga P; Zampaglioni N
    Am J Vet Res; 1990 Nov; 51(11):1773-8. PubMed ID: 2240805
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply.
    Shore ND; Cooperberg MR; Tomlins SA
    JAMA Oncol; 2023 Jan; 9(1):150-151. PubMed ID: 36385364
    [No Abstract]   [Full Text] [Related]  

  • 75. Introduction to the seminar series: Optimal management during ADT to mitigate complications.
    Higano CS
    Urol Oncol; 2020 Feb; 38(2):44. PubMed ID: 30528887
    [No Abstract]   [Full Text] [Related]  

  • 76. [Antiandrogen withdrawal syndrome].
    Komiya A; Kato T; Yasuda K; Watanabe A; Okumura A
    Nihon Rinsho; 2016 May; 74 Suppl 3():584-8. PubMed ID: 27344798
    [No Abstract]   [Full Text] [Related]  

  • 77. Impact of Androgen Deprivation Therapy on High-level Physical Performance.
    Grossmann M; Cheung AS
    Eur Urol; 2016 Jun; 69(6):1161-2. PubMed ID: 26827095
    [No Abstract]   [Full Text] [Related]  

  • 78. Urethral stricture following antiandrogen therapy.
    Yokoyama M; Fukutani K; Kawamura T; Shoji F; Ohtani M
    J Urol; 1982 Feb; 127(2):342-3. PubMed ID: 7062401
    [No Abstract]   [Full Text] [Related]  

  • 79. Molecular analysis of the androgen receptor.
    Wilson EM; Simental JA; French FS; Sar M
    Ann N Y Acad Sci; 1991; 637():56-63. PubMed ID: 1785790
    [No Abstract]   [Full Text] [Related]  

  • 80. Pharmacology and clinical use of antiandrogens: a short review.
    Neumann F
    Ir J Med Sci; 1982 Mar; 151(3):61-70. PubMed ID: 7042638
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.